On June 14, 2024, Hopstem was voted first place out of 20 pitching teams by a panel of top investors and pharmaceutical executives, virtually at the 2024 annual SAPA Investment Forum and online Road Show. Hopstem’s breakthrough allogeneic iPSC-derived hNPC01 cell therapy has demonstrated good safety and sign of efficacy in chronic stroke patients in the on-going phase I study, targeting more than 21 million global patients.

The Sino-American Pharmaceutical Professionals Association (SAPA), headquartered in New Jersey, is one of the most active Chinese professional associations in the US with more than 6,000 member.（https://www.sapaweb.org/hifnr-2024）